Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-09-13 02:01 UTC

BIOMED PULSE

Sunday, September 13, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo has now reached 61 health zones across six provinces, making it the largest Ebola outbreak ever recorded in DRC history, with sustained transmission and no sign of deceleration. [1]

Mood: Tense on the outbreak front; longevity and drug-approval signals are steady but the DRC-Uganda Ebola crisis dominates global concern.

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) - DRC AND UGANDA: RECORD-BREAKING OUTBREAK

  • As of September 10, 2026, the Bundibugyo virus disease (BVD) outbreak in DRC has expanded to 61 health zones, up from 60 in the prior WHO Disease Outbreak News update of August 28, 2026. [1] [2]
  • The newly added health zone is Kayna, located in North Kivu Province; the six affected provinces are Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, and Tshopo. [1]
  • WHO's August 14 DON described this as the largest Ebola outbreak ever reported in DRC and noted it is expanding faster than any previous Ebola outbreak, with sustained transmission as the dominant driver. [3]
  • As of July 15, 2026, cumulative confirmed cases stood at 2,124 with 828 confirmed deaths; updated totals reflecting the September 10 report are not yet available but trajectory remains sharply upward. [4]
  • Cross-border spread to Uganda was confirmed earlier in the outbreak; WHO continues to characterize cross-border transmission as an ongoing risk. [5] [6]
  • CDC mobilized an international Ebola response beginning May 17, 2026, and enhanced airport Ebola screening was activated at Washington-Dulles and Atlanta Hartsfield-Jackson airports in late May 2026. [7] [8]

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • WHO's fifth Disease Outbreak News on the Andes hantavirus (ANDV) cluster, published July 2, 2026, confirms ongoing follow-up of cases linked to the M/V Hondius cruise ship first reported May 2, 2026. [9]
  • The original cluster involved 147 passengers and crew; two laboratory-confirmed cases of ANDV and five suspected cases were identified in the first WHO DON on May 4, 2026. [10]
  • Subsequent updates through June 24, 2026 confirmed additional cases; Andes hantavirus causes hantavirus pulmonary syndrome, a severe respiratory illness with significant case-fatality risk.

MEASLES - BANGLADESH

  • WHO reported on April 23, 2026 that Bangladesh notified 19,161 suspected measles cases and 2,897 laboratory-confirmed cases affecting 58 of 64 districts across all eight divisions of the country.
  • Bangladesh's outbreak follows a global pattern: WHO and CDC reported 10.3 million measles infections worldwide in 2023, a surge driven by vaccination coverage gaps.

CYCLOSPORA - TACO BELL / ICEBERG LETTUCE, UNITED STATES

  • CDC identified shredded iceberg lettuce served at Taco Bell locations as the source of a Cyclospora cayetanensis outbreak affecting five states, with 1,644 people reported sick as of July 17, 2026.
  • The outbreak subsequently expanded to four additional states by July 24, 2026; CDC's Cyclospora response transcript was posted July 14, 2026.

SALMONELLA AND FOOD-BORNE OUTBREAKS - ONGOING U.S. ALERTS

  • CDC warns of a Salmonella outbreak linked to jalapeños as of August 5, 2026; a separate dual Salmonella and E. coli outbreak linked to recalled alfalfa sprouts was announced August 21, 2026.
  • An E. coli outbreak linked to frozen blueberries prompted a recall alert on July 7, 2026.
  • CDC's Metabolic Meals home-delivery Salmonella outbreak investigation, posted September 5, 2026, reports 16 people ill across 10 states.

DRUG-RESISTANT SALMONELLA - MORINGA PRODUCTS

  • CDC's extensively drug-resistant Salmonella outbreak linked to moringa powder capsules, confirmed February 13, 2026, resulted in three hospitalizations; a broader moringa-leaf alert issued May 27, 2026 noted a growing number of illnesses and outbreaks across multiple product lines.

NIPAH VIRUS - INDIA

  • WHO confirmed one laboratory-confirmed Nipah virus (NiV) infection in Kozhikode district, Kerala, India on June 25, 2026; the adult male patient developed neurological symptoms on May 30, 2026 and was hospitalized June 10, 2026.

YELLOW FEVER - GLOBAL

  • From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; transmission carried over from elevated activity in the Americas in 2025.

WEST NILE VIRUS - UNITED STATES

  • CDC reported an early and record West Nile virus season in the United States as of July 1, 2026, urging mosquito-bite prevention during the July 4 holiday weekend.

DRUG-RESISTANT BACTERIA - U.S. TREND

  • A CDC report released September 23, 2025 found a dramatic increase in dangerous drug-resistant bacteria in U.S. healthcare settings, continuing a trend flagged in earlier surveillance data.

🧬 LONGEVITY & AGING

NAD+ MEASUREMENT VALIDATION TRIAL - CLINICAL LONGEVITY BIOMARKER

  • A ClinicalTrials.gov-registered study (NCT07416786) is measuring nicotinamide adenine dinucleotide (NAD+) levels in healthy adults before and after supplementation with over-the-counter nicotinamide riboside (NR), using magnetic resonance spectroscopy (MRS) to validate NAD+ as a reliable human clinical biomarker.
  • NAD+ declines with age and is mechanistically linked to mitochondrial function, DNA repair, and sirtuin activity; accurate non-invasive measurement is a key bottleneck for longevity intervention trials.

MULTI-COMPONENT NUTRITION AND INTRINSIC CAPACITY IN OLDER ADULTS

  • A ClinicalTrials.gov study (NCT07815158) is evaluating a 12-week multi-component nutritional formula against WHO Integrated Care for Older People (ICOPE) intrinsic capacity domains - covering cognitive, locomotor, sensory, vitality, and psychological function - plus physical function and metabolic biomarkers in community-dwelling older adults.
  • The WHO ICOPE framework treats intrinsic capacity as the composite of all mental and physical capacities of an individual, making this a directly longevity-relevant endpoint construct.

PARKINSON'S DISEASE AND MILD COGNITIVE IMPAIRMENT - VR REHABILITATION

  • The OPERA pilot study (NCT06920511) is evaluating a bio-cooperative robotic platform (PRoBio) for cognitive rehabilitation in patients with Parkinson's Disease and Mild Cognitive Impairment (MCI), an open-label single-arm interventional trial.
  • Cognitive decline and Parkinson's disease are major contributors to reduced healthspan in aging populations; digitally assisted rehabilitation represents a non-pharmacological longevity-adjacent intervention avenue.

TIMOR-LESTE CERTIFIED MALARIA-FREE

  • WHO certified Timor-Leste malaria-free on July 24, 2025, crediting a nationwide response launched shortly after the country gained independence in 2002; eliminating malaria removes a significant driver of premature mortality and reduced life expectancy.

💊 NEW CURES & APPROVALS

ETCAMAH (CAMIZESTRANT) - ASTRAZENECA, NDA220359

  • AstraZeneca Pharmaceuticals LP received an original approval action (ORIG AP) for ETCAMAH, with active ingredient camizestrant, under NDA220359; camizestrant is an oral selective estrogen receptor degrader (SERD) being developed for estrogen receptor-positive breast cancer.

HYRNUO (SEVABERTINIB) - BAYER HEALTHCARE, NDA219972

  • Bayer Healthcare received a supplemental approval action (SUPPL AP) for HYRNUO, with active ingredient sevabertinib, under NDA219972; sevabertinib is a kinase inhibitor in the cancer targeted-therapy class.

IBRUTINIB GENERIC - HETERO LABS LTD V, ANDA211182

  • Hetero Labs Ltd V received an original generic approval (ORIG AP) for ibrutinib under ANDA211182; ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor used in B-cell malignancies including chronic lymphocytic leukemia and mantle cell lymphoma.

BRIVARACETAM GENERIC - ZHEJIANG JUTAI PHARM, ANDA220136

  • Zhejiang Jutai Pharm received an original generic approval (ORIG AP) for brivaracetam under ANDA220136; brivaracetam is a third-generation antiseizure medication that binds synaptic vesicle protein 2A (SV2A).

TAPENTADOL HYDROCHLORIDE GENERIC - MSN, ANDA220865

  • MSN received an original generic approval (ORIG AP) for tapentadol hydrochloride under ANDA220865; tapentadol is a centrally acting opioid analgesic with dual mu-opioid receptor agonist and norepinephrine reuptake inhibitor mechanisms.

TOPIRAMATE GENERIC - MICRO LABS, ANDA219183

  • Micro Labs received an original generic approval (ORIG AP) for topiramate under ANDA219183; topiramate is used for epilepsy and migraine prophylaxis and is a component of weight-management combination therapy.

AMELUZ (AMINOLEVULINIC ACID HCL) - BIOFRONTERA, NDA208081

  • Biofrontera received a supplemental approval action (SUPPL AP) for AMELUZ, active ingredient aminolevulinic acid hydrochloride, under NDA208081; AMELUZ is a photosensitizer used in photodynamic therapy for actinic keratosis and field cancerization.

🧪 CLINICAL TRIALS

NAD+ BIOMARKER VALIDATION (NCT07416786)

  • Sponsor-unspecified study registered September 11, 2026 seeks to validate NAD+ measurement via MRS in healthy adults supplemented with nicotinamide riboside (NR); goal is standardizing NAD+ as a longevity clinical endpoint for future therapeutic trials.

GILTERITINIB PLUS VENETOCLAX PLUS AZACITIDINE IN FLT3-MUTANT AML (NCT05520567)

  • Trial updated September 11, 2026 tests triple-combination therapy in newly diagnosed acute myeloid leukemia patients with FLT3 gene mutations; gilteritinib targets FLT3, venetoclax inhibits BCL-2, and azacitidine is a hypomethylating agent.

PACRITINIB IN MDS AND MDS/MPN (NCT06303193)

  • Trial updated September 11, 2026 tests pacritinib, a multi-kinase inhibitor targeting CSF1R, IRAK1, JAK2, and FLT3, in adults and pediatric participants aged 12 and older with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

MULTI-COMPONENT NUTRITION AND OLDER ADULT INTRINSIC CAPACITY (NCT07815158)

  • 12-week interventional trial registered September 11, 2026 uses WHO ICOPE domains as primary endpoints in community-dwelling older adults, measuring physical function and metabolic biomarkers alongside nutritional supplementation.

TMS FOR OPIOID USE DISORDER DECISION-MAKING (NCT06577454)

  • Trial updated September 11, 2026 investigates whether transcranial magnetic stimulation (TMS) applied to specific brain regions alters risky and ambiguous decision-making in people with and without opioid substance use disorder.

RISANKIZUMAB IN PEDIATRIC ULCERATIVE COLITIS (NCT07071519)

  • AbbVie-sponsored study updated September 11, 2026 assesses pharmacokinetics, safety, and efficacy of risankizumab, an IL-23 inhibitor, in pediatric ulcerative colitis patients.

📢 PUBLIC HEALTH

OBESITY PREVALENCE DATA - UNITED STATES 2023

  • CDC data released September 12, 2024 show that in 23 U.S. states, more than one in three adults (35% or higher) now has obesity; before 2013 no state had reached the 35% threshold.

CONGENITAL SYPHILIS - 12TH CONSECUTIVE YEAR OF INCREASE

  • CDC data published September 24, 2025 show U.S. cases of syphilis in newborns increased for the 12th consecutive year in 2024, reflecting ongoing gaps in prenatal STI screening and treatment.

DRUG OVERDOSE DEATHS - DECLINING

  • CDC data from May 2025 show a 27% decrease in drug overdose deaths in 2024, continuing the trend of a nearly 24% decline reported in February 2025; fentanyl-related prevention efforts are credited.

LISTERIA - ONGOING OUTBREAK LINKED TO PREPARED MEALS

  • CDC continues warning consumers to check refrigerators and freezers for recalled prepared meal products linked to an ongoing Listeria monocytogenes outbreak; as of October 30, 2025, illnesses were continuing despite recalls.

WEST NILE EARLY SEASON - MOSQUITO PREVENTION

  • CDC flagged a record-early West Nile virus season in the United States as of July 2026, advising use of EPA-registered insect repellents, wearing long sleeves, and eliminating standing water around homes.

CDC BIOSURVEILLANCE MILESTONE

  • CDC's Traveler-Based Genomic Surveillance program surpassed one million voluntary air travel participants as of January 30, 2026, strengthening pathogen detection at U.S. ports of entry.

U.S. WHO WITHDRAWAL COMPLETED

  • The United States formally completed its withdrawal from the World Health Organization on January 22, 2026; WHO stated the decision makes both the United States and the world less safe and said issues related to the withdrawal would be considered by the WHO Executive Board and World Health Assembly.

BIOMED PULSE is informational only and does not constitute medical advice. Always consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  6. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  7. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  9. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  10. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260913-02-v74 · 2026-09-13 02:01 UTC · pulse.uzylab.com

Read next